Russ Lehrman, PhD

Founder, CEO | BioSuperior Technology, Inc.
March of Dimes
Russ Lehrman

Biography

Dr. Russ Lehrman, is the Founder and CEO of BioSuperior Technology, Inc. a biotechnology company that is creating therapeutics for respiratory disease. He is passionate about the company mission. BioSuperor is developing a therapeutic for lung inflammation in preterm infants, a disease known as bronchopulmonary dysplasia (BPD). BPD is a serious unmet medical need that occurs in 10,000 to 15,000 preterm infants each year and leads to increased death or diseases such as pulmonary hypertension, asthma, chronic obstructive pulmonary disease, and neurodevelopmental impairment. With the help of  March of Dimes, Dr. Lehrman and colleagues have manufactured and characterized a drug candidate for the treatment of this disease. Over the course of his industrial career, Dr. Lehrman has helped develop therapeutics for diverse diseases such as multiple sclerosis, adult macular degeneration, and diabetes. Some of these products have captured over $1B in annual revenue. He is also a Stanford Medical School Advisor as part of the SPARK Program, and previously served as Adjunct Professor at the University of Kansas – School of Pharmacy. In addition to the March of Dimes, the research being conducted by Dr. Lehrman is supported by the National Science Foundation.

Education

PhD University of Wisconsin – School of Pharmacy – Madison, WI

BSc Chemistry McGill University, Montreal, P.Q.

Honors and recognition

March of Dimes Grant #23-FY20-221, “Development of a Synthetic Lung Surfactant for the Treatment of Neonatal Respiratory Distress Syndrome”

March of Dimes Grant #23-FY21-12, “Cost-effective, Scaleable Development of Novel Synthetic Lung Surfactant.”

NSF – STTR Phase 1 Award #2210373, “Bioengineering lung surfactant for the treatment of respiratory disease”. (June 2022)

Invited Higuchi Lecture, “Protein Stability In Amorphous Powders”. (May 2002)

Invited lecture series at the University of Kansas, School of Pharmacy: “Inhalation Technology: Biotechnology Applications” (April, 2000)

Selected publications

  1. S.R. Lehrman, J.P. Bridges, E.F. Redente, E. Goldin, US 63/343,334, “Delivery of Focal Adhesion Kinase for treating Vascular and/or Capillary Tissue Injury”, Filed 2022.
  2. S.R. Lehrman, Ehud Goldin “Lung Treatment Compositions”, PCT/US2021/055333, Filed 2021
  3. D. L. Medin and S.R. Lehrman, “Nucleic Acid Classification”, US 10,597,704, Issued 2020.
  4. D.J. Burke, S.E. Buckley, S.R. Lehrman, B.H. O’Connor, J. Callaway, and C.P. Phillips, "Immunoglobulin Formulation and Method of Preparation Thereof", US 8,349,321, Issued 2012.
  5. S.R. Lehrman, “Protein Aggregation: Relevance to Pharmaceutical Development and Disease Pathology”, AAPS News Magazine, June, 2008.
  6. C. Stevenson, J.E. Hastedt, S.R. Lehrman, H.-S. Chiang, D.B. Bennett, D. Lesikar, B.Yang, D. Gong, and K. Cabot, “Inhalable Spray-Dried 4-Helix Bundle Protein Powders Having Minimized Aggregation”, U.S. Patent 6,838,075, Issued 2005.
  7. H.-K. Chan, A. Clark, M.-C. Kuo, S.R. Lehrman, K. Pikal-Cleland, D.P. Miller, R.Vehring, and D. Lechuga-Ballesteros, "Physical Stability of Salmon Calcitonin Spray-Dried Powders for Inhalation", J.Pharm.Sci. 93(3), 792-804 (2004).
  8. S.R. Lehrman, H.A. Havel, J.L. Tuls, S.M. Plaisted, and D.N. Brems, "Somatotropin Analogs", US 5,663,305, Issued 1997.
  9. S.R. Lehrman, J.L. Tuls, H.A. Havel, R.J. Haskell, S.D. Putnam, and C-S.C. Tomich, "Site-Directed Mutagenesis to Probe Protein Folding: Evidence that the Formation and Aggregation of a Bovine Growth Hormone Folding Intermediate Are Dissociable Properties", Biochemistry 30, 5777-5784 (1991).
  10. S.R. Lehrman, "Protein Structure", in Fundamentals of Protein Biotechnology, S.Stein, ed., Marcel Dekker Inc., New York, pp. 9-38 (1991).

Weblinks